Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E

Abstract

A 74-year-old female has been diagnosed with stage IIIB rectal cancer in 2003. Following anterior resection, she received adjuvant chemotherapy with three different regimens. In August 2005, she was started on a modified FOLFOX6 regimen, and the sixth cycle of chemotherapy induced a severe hypersensitivity reaction (HSR). Immediate cessation of the infusion resulted in a disappearance of the allergic reaction 60 min later. Blood tests just after the reaction demonstrated a marked elevation of immunoglobulin E to 300 IU L^-1 (normal range: <170 IU L^-1). This change implies the involvement of a type I reaction in the HSR. In addition, a drug lymphocyte stimulating test against oxaliplatin and levofolinate calcium (an isomer of leucovorin calcium) gave values of 696% and 107 % respectively, as compared with control serum. This suggests that the patient had an adverse reaction not only of type I but partly of type IV allergic reaction also. Oxaliplatin appears to have caused a HSR in this Japanese patient, and thus pharmacists, physicians, and other medical staff must keep a careful watch of a patient's clinical condition during chemotherapy including oxaliplatin. J Oncol Pharm Practice (2007) 13: 233—235.

Keywords

oxaliplatin FOLFOX hypersensitivity reaction anaphylaxis immunoglobulin E

Get full access to this article

View all access options for this article.

References

Goldberg RM , Sargent DJ , Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23—30.

de Gramont A. , Figer M. , Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol 2000; 18: 2938—47.

Siu SW , Chan RT , Au GK Hypersensitivity reactions to oxaliplatin: experience in a single institute . Ann Oncol 2006; 17: 259—61.

Gonzalez-Mahave I. , Lobera Iabairu T , Blasco Sarramian A et al. Anaphylaxis produced by oxaliplatin . J Invest Allergol Clin Immunol 2005; 15: 75—77.

Thomas RR , Quinn MG , Schuler B. et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin . Cancer 2003; 97: 2301—07.

Maindrault-Goebel F. , Andre T. , Tournigand C. et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41: 2262—67.

Meyer L. , Zuberbier T. , Worm M. et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002; 20: 1146—47.

Saif MW

Hypersensitivity reactions associated with oxaliplatin. Expert Opin

Drug Saf 2006; 5: 687—94.

Hewitt MR , Sun W.

Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal

Cancer 2006; 6: 114—17.

10.

Garufi C. , Cristaudo A. , Vannni B. et al.. Skin testing and hypersensitivity reactions to oxaliplatin . Ann Oncol 2003; 14: 497—98.

11.

Shlebak AA , Clark PI , Green JA Hypersensitivity and cross reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 1995; 35: 349—51.

12.

Sliesoraitis S. , Chikhale PJ Carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15: 13—18.

13.

de Vries RS , Mattijssen EJ , van Sorge AA Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 2006; 17: 1723—24.

14.

Cleare MJ , Hughes EG , Jacob B. et al.. Immediate (type I) allergic responses to platinum compounds . Clin Allergy 1976; 6: 183—95.

15.

Merk HF Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines . Toxicology 2005; 209: 217—20.